第三代BCR-ABL酪氨酸激酶抑制剂普纳替尼  

Third generation BCR-ABL tyrosine kinase inhibitor—ponatinib

作　　者：邹彬镔[1,2] 石庆之[1] 

机构地区：[1]南昌大学第二附属医院血液科,江西南昌330006 [2]南昌大学研究生院医学部,江西南昌330006

出　　处：《中国新药与临床杂志》2014年第5期329-333,共5页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：普纳替尼作为新一代酪氨酸激酶抑制剂(TKIs),对BCR-ABL阳性白血病,如慢性髓细胞白血病(CML)、费城染色体阳性急性淋巴细胞性白血病(Ph+ALL)有显著的治疗效果,甚至在对当前市场上供应的第一、二代TKIs出现耐药(如T315I突变)的情况下仍有效。目前普纳替尼已获美国FDA批准用于对其他TKIs耐药的CML与Ph+ALL患者的治疗,并在尼洛替尼与达沙替尼耐药或不耐受的T315I突变患者中进行了Ⅱ期临床研究。Ponatinib as a new generation of tyrosine kinase inhibitors, for the BCR- ABL positive leukemia such as chronic myelogenous leukemia, Philadelphia chromsome-positive acute lymphocytic leukemia, which have a significant therapeutic effect, even in the current market supply of tyrosine kinase inhibitor for the emergence of resistant cases, such as T315I mutation, is still valid. Recently, the U.S. Food and Drug Administration has given expedited approval to ponatinib for patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia who have developed resistance to other tyrosine kinase inhibitors, and a Phase H study evaluated ponatinib in patients who were resistant or intolerant to nilotinib or dasatinib or patients who had the T315I mutation.

关 键 词：普纳替尼 蛋白酪氨酸激酶类 靶向治疗 白血病 抗肿瘤药 

分 类 号：R979.1[医药卫生—药品]